Magle Chemoswed Holding's Annual Report for 2021 has been published on the Group’s website as of today
The annual report is available as a downloadable PDF document at www.maglegroup.com
"The positive results for 2021 were made possible by our dedicated teams and our innovative lineup of products and services. The strong performance across our business areas supported our increased non-capitalised investment in research and development of our medical technology (DSM). The acquisition of PharmaCept drove our ambitious plans for a go-to-market sales team for our DSM products delivering to expectations in 2021. In addition, the robust customer response to our contract manufacturing and development services through our CDMO business drove growth in revenue and earnings," said Justin Pierce, Magle Chemoswed's CEO.
Petra Jönsson Sjölin, Magle Chemoswed's CFO, said, "These operating results supported our investments across our business areas and provided a good platform to balance risk and investment whilst implementing our growth strategy".